000007588 001__ 7588
000007588 005__ 20231129124940.0
000007588 0247_ $$2DOI$$a10.6083/9w0323552
000007588 037__ $$aETD
000007588 245__ $$aSecondary analyses of dietary data from PRISM  clinical trials to evaluate safety and efficacy of pegvaliase for adults with PKU
000007588 260__ $$bOregon Health and Science University
000007588 269__ $$a2019
000007588 336__ $$aThesis
000007588 502__ $$bM.S.
000007588 520__ $$aPhenylketonuria (PKU) is a genetic disorder caused by a deficiency of phenylalanine hydroxylase leading to decreased conversion of phenylalanine (Phe) to tyrosine (Tyr). Pegvaliase™ (Palynziq™, BioMarin Pharmaceutical Inc., Novato, CA, USA), an injectable enzyme replacement therapy decreases plasma Phe by converting Phe intro trans-cinnamic acid and ammonia. This study aims to evaluate the changes in the dietary composition of participants with PKU on pegvaliase.
000007588 650__ $$aDietary Proteins$$017788
000007588 650__ $$aDiet Therapy$$017779
000007588 6531_ $$atherapeutic use
000007588 6531_ $$apegvaliase
000007588 6531_ $$aphenylketonuria
000007588 691__ $$aSchool of Medicine$$041369
000007588 7001_ $$aKhoo, Vi V.
000007588 8564_ $$9326436c0-cf6d-4c64-995e-59da2eeb8ab1$$s2326938$$uhttps://digitalcollections.ohsu.edu/record/7588/files/khoo.vivien.2019.pdf
000007588 905__ $$a/rest/prod/9w/03/23/55/9w0323552
000007588 909CO $$ooai:digitalcollections.ohsu.edu:7588$$pstudent-work
000007588 980__ $$aTheses and Dissertations